# Run 0 response, Temperature =0.0:

```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1 (Gel + GelMA),6,7,8,5,6,5,37
Formula 2 (PAM + Gel),8,7,7,6,6,6,40
Formula 3 (Chitosan + GelMA),7,6,7,5,4,3,32
Formula 4 (GelMA + Silk Fibroin),9,6,8,6,7,6,42
Formula 5 (GelMA + PEG),8,8,8,8,8,8,48
Formula 6 (Starch + GelMA),6,6,7,6,6,7,38
Formula 7 (Chitin + GelMA),8,6,7,5,3,3,32
Formula 8 (GelMA + Cellulose),9,7,8,7,8,8,47
Formula 9 (PAM + PVA),9,7,4,8,8,8,44
Formula 10 (PAM + PEG),8,8,4,8,8,8,44
```

2. THE WINNER (Calculated Result)
- Selected Formula: Gelatin_methacrylate (GelMA) & Polyethylene_glycol (PEG) [Formula 5]
- One-Sentence Rationale: It achieves the best-balanced, tunable match to coronary artery mechanics while offering high-but-controllable swelling, strong endothelial compatibility, SMC suppression, low inflammation, and low thrombogenicity.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: Reference range used for human coronary artery Young’s modulus: 0.2–1.2 MPa (soft tissue tensile/indentation data). GelMA-PEG IPNs/co-networks can be tuned via solid content, PEGDA functionality, GelMA degree of methacrylation, and crosslink density to reliably land in ~0.3–1.0 MPa at 37°C, within the stated range.
- Swelling Profile: PEG provides high water uptake for conformability and drug loading; incorporating GelMA and using higher crosslink density (and/or higher PEG functionality) yields a controlled swelling ratio that preserves luminal patency. Practically, pre-equilibrating the liner ex vivo and designing a thin wall (and/or anistropic constraint) keeps post-implant expansion below occlusive thresholds while maintaining surface hydration for hemocompatibility.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Endothelialization: GelMA offers RGD-rich, bioactive adhesion promoting rapid endothelial coverage; PEG reduces nonspecific protein adsorption, lowering competitive fouling and supporting a cleaner EC-seeding environment.
  - SMC-inhibition: PEG-rich, low-fouling character diminishes SMC adhesion and phenotypic switching; pairing with limited, well-distributed GelMA sites biases healing toward an endothelial monolayer rather than neointimal thickening.
  - Anti-inflammation: PEG surfaces attenuate protein adsorption and macrophage activation; GelMA degrades to peptides with generally benign profiles when sourced and purified well.
  - Thrombogenicity: PEG’s antifouling character reduces fibrinogen adsorption and platelet adhesion/activation; the GelMA fraction provides needed endothelial compatibility without excessive thrombogenicity when PEG is prevalent at the interface.
- Potential "Red Flags" & Phantom Factors:
  - Photochemistry residues: Unreacted methacrylates or photoinitiator (e.g., TPO/LAP) can be inflammatory/cytotoxic; requires thorough polymerization control and post-cure washing.
  - Source variability: Animal-derived gelatin can introduce immunogenicity/endotoxin risk; mitigate via recombinant human gelatin or high-purity medical-grade gelatin.
  - PEG hypersensitivity: Rare anti-PEG antibodies and complement activation have been reported clinically; risk appears lower for bulk hydrogel surfaces than for PEGylated injectables but warrants vigilance.
  - Long-term mechanics: GelMA is enzymatically degradable; if the design requires durable support, the PEG fraction should maintain backbone integrity and modulus within the 0.2–1.2 MPa window over time, or degradation kinetics must be tuned to avoid late softening.
  - Swelling occlusion risk: High PEG content can swell substantially; must be constrained by geometry, crosslinking, and pre-hydration to avoid lumen narrowing, especially in small-caliber coronaries.

5. REJECTED CANDIDATES (Brief Autopsy)
- Rejected primarily due to thrombosis risk (score ≤3):
  - Formula 3 (Chitosan + GelMA): Cationic chitosan is pro-coagulant and pro-inflammatory.
  - Formula 7 (Chitin + GelMA): Similar pro-coagulant, immunostimulatory behavior; low anti-inflammation score.
- Marginal endothelialization (score =4), limiting healing and re-endothelial coverage:
  - Formula 9 (PAM + PVA), Formula 10 (PAM + PEG): Low bioactivity leads to poor EC adhesion despite good hemocompatibility and SMC suppression.
- Less optimal swelling control or mechanical confidence:
  - Formula 1 (Gel + GelMA): Gelatin’s thermal weakness at 37°C shifts reliance to GelMA; modulus often sub-target without heavy crosslinking; moderate thrombogenicity.
  - Formula 6 (Starch + GelMA): Superabsorbent tendency risks lumen narrowing unless tightly constrained; mechanics are modest.
- Strong contenders but slightly lower balance than the winner:
  - Formula 4 (GelMA + Silk Fibroin): Excellent modulus tunability and EC compatibility, but moderate thrombogenicity and lower swelling latitude.
  - Formula 8 (GelMA + Cellulose): Near-tie; great mechanics and hemocompatibility, but nanocellulose reinforcement tends to reduce swelling headroom compared with PEG, slightly lowering deployment/drug-loading flexibility.

# Run 1 response, Temperature =0.0:

```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1,8,7,9,6,7,6,43
Formula 2,8,7,8,7,7,6,43
Formula 3,8,6,7,6,5,4,36
Formula 4,8,6,9,5,8,6,42
Formula 5,9,8,8,8,9,8,50
Formula 6,7,6,8,6,7,6,40
Formula 7,7,5,7,6,4,4,33
Formula 8,8,7,8,6,6,6,41
Formula 9,8,8,4,8,7,8,43
Formula 10,8,9,3,9,8,9,46
```

2. THE WINNER (Calculated Result)
- Selected Formula: Formula 5 (GelMA & PEG)
- One-Sentence Rationale: It best balances artery-matched mechanics and high-yet-controllable swelling with superior hemocompatibility and inflammation control, while still supporting endothelialization and discouraging SMC overgrowth.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: Reference range used for human coronary artery Young’s modulus (physiologic strain) = 0.2–1.0 MPa (200–1000 kPa). GelMA-PEG networks can be tuned within this window by adjusting GelMA methacrylation, polymer wt%, and PEG crosslinker length/density; a target of ~0.3–0.8 MPa is realistic and stable in physiological hydration.
- Swelling Profile: PEG-rich networks provide high equilibrium swelling for conformal apposition and payload capacity, while GelMA content and crosslink density keep swelling predictable and mechanically stable in the swollen state. Lumen safety: pre-equilibrate the liner before implantation; use modest PEG fraction and higher GelMA crosslinking near the blood-contacting surface to limit radial (inward) expansion; optional anisotropic reinforcement (non-swelling hoop fibers) to cap radial swelling while preserving axial compliance.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Endothelialization: GelMA provides inherent cell-adhesive motifs (e.g., RGD), supporting rapid endothelial coverage without requiring additional ligands.
  - SMC-inhibition: PEG’s anti-fouling character reduces SMC adhesion/migration; pairing with moderate GelMA surface ligand density can bias for endothelial over SMC colonization.
  - Anti-inflammation: PEG is protein-resistant and minimizes complement activation; GelMA degrades to native-like peptides with typically mild immunogenicity.
  - Thrombogenicity: PEG-rich surfaces reduce nonspecific protein adsorption and platelet adhesion; GelMA fraction can be heparinized or NO-donor–doped if further thrombosis control is needed.
- Potential "Red Flags" & Phantom Factors:
  - Over-swelling risk: Unchecked PEG-dominant networks can over-expand; mitigate via pre-hydration, crosslink gradient, and hoop-reinforcement to restrict radial swelling.
  - Photochemistry residues: Unreacted methacrylate and photoinitiators (e.g., Irgacure 2959/LAP) can be cytotoxic; require validated purification and high conversion (>90%).
  - Platelet interaction of gelatin: Although lower than collagen, GelMA can still bind platelets; surface heparinization, zwitterionic grafts, or NO release can provide safety margin.
  - Degradation chemistry: If degradable PEG esters are used, slow hydrolysis can release acidic species; maintain buffering capacity and favor stable linkages for chronic implants.

5. REJECTED CANDIDATES (Brief Autopsy)
- Elevated thrombosis risk (cationic polysaccharides):
  - Formula 3 (CS & GelMA), Formula 7 (Chitin & GelMA): Cationic backbones increase platelet/protein adsorption; chitin also carries higher inflammatory potential. Both scored 4 in Thrombogenicity; Formula 7 also scored 4 in Anti-inflammation.
- Endothelialization deficits (anti-fouling synthetics lacking cell-adhesive motifs):
  - Formula 10 (PAM & PEG): Strong anti-fouling led to Endothelialization = 3 (below threshold) despite excellent SMC-inhibition and hemocompatibility.
  - Formula 9 (PAM & PVA): Borderline Endothelialization = 4; would likely require biofunctionalization to be competitive.
- Swelling instability or uncertain processing:
  - Formula 6 (Starch & GelMA): High swelling with comparatively lower network robustness; moderate scores across categories but no standout strengths.
  - Formula 7 (Chitin & GelMA): Limited solubility/processability of chitin and lower swelling controllability; added inflammatory/thrombotic concerns.
- Good but outperformed on risk-balanced optimization:
  - Formula 1 (Gel & GelMA), Formula 2 (PAM & Gel), Formula 4 (GelMA & Silk), Formula 8 (GelMA & Cellulose): All tunable to the mechanical window and acceptable swelling; however, each carries a relative trade-off (higher platelet interaction with gelatin surfaces; PAM/gel still moderate thrombogenicity; silk reduces swelling and may not discourage SMC; cellulose adds modest hemocompatibility but less anti-fouling than PEG) that left them short of Formula 5’s balanced profile.

# Run 2 response, Temperature =0.0:

```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1,8,8,9,5,7,4,41
Formula 2,9,6,7,6,6,5,39
Formula 3,7,7,8,4,4,3,33
Formula 4,8,6,8,4,6,5,37
Formula 5,9,9,8,8,8,8,50
Formula 6,6,6,7,6,6,6,37
Formula 7,6,5,7,6,4,5,33
Formula 8,8,7,8,7,7,6,43
Formula 9,9,8,5,9,7,8,46
Formula 10,9,8,4,9,8,9,47
```

2. THE WINNER (Calculated Result)
- Selected Formula: Formula 5 (GelMA + PEG)
- One-Sentence Rationale: It achieves the best-balanced profile—artery-matched modulus, high yet controllable swelling, strong endothelial support with PEG-mediated SMC inhibition, and low thrombogenicity/inflammation—yielding the highest total score with no sub-4 risks.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: Using a coronary artery Young’s modulus reference of 0.2–1.0 MPa (physiological strain, soft-tissue tensile/compressive testing), GelMA+PEG networks can be tuned (methacrylation degree, PEG MW and crosslink density) to land squarely within this range while retaining elasticity, hence Mechanical_Safety = 9.
- Swelling Profile: PEG provides high, predictable water uptake and GelMA confers structural integrity; crosslink gradients and network density allow high swelling for conformability/drug loading without uncontrolled radial expansion. This supports deployment and wall conformation while avoiding lumen occlusion, hence Swelling_Performance = 9.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Endothelialization: GelMA provides RGD-like motifs and ECM-like cues for rapid endothelial coverage (score 8).
  - SMC-inhibition: PEG’s anti-fouling surface reduces SMC adhesion/migration; pairing with artery-like stiffness favors a contractile SMC phenotype over synthetic (score 8).
  - Anti-inflammation: PEG reduces protein adsorption and complement activation relative to bioactive collagens; GelMA’s degradation peptides are generally benign at physiological pH (score 8).
  - Thrombogenicity: PEG-rich luminal surface lowers platelet adhesion and fibrin formation; once endothelialized, thrombotic risk further drops (score 8).
- Potential "Red Flags" & Phantom Factors:
  - Thrombogenicity depends on surface presentation: exposed GelMA domains can elevate platelet adhesion. Mitigation: PEG-over-GelMA surface bias, heparin/NO topcoats if needed.
  - Photoinitiator and residual methacrylate leachables (e.g., Irgacure/LAP) can be cytotoxic. Mitigation: low-tox initiators, high conversion, exhaustive post-cure rinsing.
  - PEG oxidative byproducts (trace carbonyls/peroxides) over long-term implantation. Mitigation: antioxidant stabilization, end-capping, and surface scavengers.
  - Immunology: rare anti-PEG hypersensitivity has been reported clinically. Mitigation: use lower-MW, end-capped PEG and thorough risk screening; consider alternative hydrophiles if patient risk is high.
  - Swelling containment: ensure anisotropic/graded crosslinking or prehydration so radial swelling is capped and wall-conformity is prioritized.

5. REJECTED CANDIDATES (Brief Autopsy)
- Rejected due to Thrombosis Risk:
  - Formula 3 (Chitosan + GelMA): chitosan’s intrinsic hemostatic/platelet-activating nature (Thrombogenicity = 3) with pro-inflammatory signaling; fails safety-first mindset.
  - Borderline: Formula 1 (Gel + GelMA) and Formula 4 (GelMA + Silk) show moderate platelet adhesion risk without anti-fouling mitigation.
- Rejected due to Inflammation/Hypersensitivity Concerns:
  - Formula 3 (Chitosan + GelMA) and Formula 7 (Chitin + GelMA): cationic polysaccharide/complement activation, TLR engagement; Anti_inflammation ≤4–5.
- Rejected due to Endothelialization Deficit (would require bioactive modification):
  - Formula 10 (PAM + PEG) and Formula 9 (PAM + PVA): both are inherently non-adhesive (Endothelialization ≤5); excellent hemocompatibility but risk delayed endothelialization without added ligands.
- Rejected due to Swelling Instability or Modulus Marginality:
  - Formula 2 (PAM + Gel): very high swelling potential with risk of radial overexpansion unless heavily constrained; also middling thrombogenicity.
  - Formula 6 (Starch + GelMA) and Formula 7 (Chitin + GelMA): limited mechanical headroom and/or swelling control versus PEG- or cellulose-reinforced systems.
- Strong but Outperformed:
  - Formula 8 (GelMA + Cellulose): good mechanics and biology but less anti-fouling than PEG; moderate thrombogenicity (6) kept it behind the winner.
  - Formula 9 (PAM + PVA) and Formula 10 (PAM + PEG): outstanding SMC inhibition and hemocompatibility; however, poor-to-marginal endothelialization without added ligands constrained total performance for a rapid-healing liner.

# Run 3 response, Temperature =0.0:

```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1,8,7,8,5,6,5,39
Formula 2,9,7,7,6,6,6,41
Formula 3,8,6,7,5,4,4,34
Formula 4,9,7,8,6,7,7,44
Formula 5,9,8,7,7,8,8,47
Formula 6,7,8,7,5,6,6,39
Formula 7,8,6,7,6,6,5,38
Formula 8,8,7,7,6,7,7,42
Formula 9,9,7,5,8,7,7,43
Formula 10,9,8,5,9,8,9,48
```

2. THE WINNER (Calculated Result)
- Selected Formula: Formula 10 (polyacrylamide [PAM] & poly(ethylene glycol) [PEG])
- One-Sentence Rationale: It best balances artery-matched mechanics with high-yet-controlled swelling, strong SMC inhibition, and top-tier hemocompatibility, achieving the highest total score without any sub-4 risks.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: Reference range used for “Human Coronary Artery Young’s Modulus” = 0.2–1.0 MPa (literature range for compliant coronary tissue under physiologic strain). A PAM–PEG interpenetrating/double-network hydrogel can be synthesized (by tuning PEG molecular weight, PAM content, and crosslink density) to reproducibly hit 0.2–1.0 MPa in the hydrated state, minimizing compliance mismatch and stress concentrations that drive neointimal hyperplasia.
- Swelling Profile: PEG-rich networks allow high equilibrium water content and rapid conformability; PAM confers robustness so the swollen state retains mechanical integrity. To prevent lumen occlusion while preserving high swelling: use thin-walled design, pre-equilibrate (pre-hydrate) to near-final dimensions before deployment, and impose radial swelling limits via higher crosslink density at the luminal side or fiber reinforcement. This achieves high swelling for wall conformity/drug loading without excessive radial expansion.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Thrombogenicity: PEG is strongly protein-repellent, reducing platelet adhesion/activation and coagulation cascade triggering; PAM is hydrophilic and generally hemocompatible when free monomer is minimized. Net effect: very low thrombogenicity under flow.
  - SMC-inhibition: Non-adhesive character (PEG-dominant surface) limits SMC attachment and phenotypic switching toward synthetic/proliferative states, supporting restenosis mitigation.
  - Anti-inflammation: Low protein adsorption reduces complement activation and macrophage adhesion; inert backbones minimize cytokine upregulation; no acidic byproducts expected.
  - Mechanical concordance: Tunable to artery-like compliance, mitigating disturbed shear and wall stress—a key driver for pathologic remodeling.
- Potential "Red Flags" & Phantom Factors:
  - Endothelialization Lag: PEGylated, non-fouling surfaces inherently resist endothelial cell adhesion (score 5). If long-term endothelial coverage is desired, surface micro-patterning or selective peptide tethering (e.g., low-density RGD) must be used carefully to avoid raising thrombogenicity or encouraging SMC ingrowth at edges.
  - Anti-PEG Antibodies/CARPA: Pre-existing anti-PEG antibodies in some patients can cause hypersensitivity or complement activation–related pseudoallergy. Risk mitigation: minimize leachables, covalent/stoichiometric PEG incorporation, and evaluate patient population risk.
  - Residual Monomer/Initiator: Acrylamide and photoinitiators are cytotoxic in monomeric form; stringent purification and full conversion are mandatory.
  - Long-term Stability/Fatigue: PAM–PEG is largely non-degradable; cyclic fatigue, creep, or crack propagation could occur over years. Design for crack resistance (double-network, toughening), validate under accelerated pulsatile fatigue; ensure retrieval feasibility in failure scenarios.
  - Biofouling Over Time: Even PEG can oxidize; protein resistance may diminish. Consider mild antioxidant stabilization and in vivo durability testing.

5. REJECTED CANDIDATES (Brief Autopsy)
- Elevated Thrombosis Risk (cationic/backbone-driven):
  - Formula 3 (Chitosan & GelMA): Cationic chitosan raises platelet adhesion and can trigger coagulation and inflammation (scores 4 for thrombogenicity and anti-inflammation). While tunable mechanics are achievable, the hemostatic nature is a liability for a luminal blood-contacting liner without heavy mitigation (e.g., durable heparinization).
- Stronger Pro-adhesive Cues → Weaker SMC Control (risk of neointima if not countered):
  - Formulas 1 (Gel + GelMA), 2 (PAM + Gel), 4 (GelMA + Silk Fibroin), 6 (Starch + GelMA), 7 (Chitin + GelMA), 8 (GelMA + Cellulose): All provide good endothelial cues but also broadly adhesive matrices that can permit SMC attachment/proliferation (SMC-inhibition 5–6). These can be clinically viable with added anti-SMC strategies (e.g., heparin/sirolimus) but scored lower on inherent SMC control.
- Lower Endothelialization Baseline (inert surfaces), limiting biologic integration without functionalization:
  - Formula 9 (PAM + PVA): Excellent mechanics/hemocompatibility and good SMC control, but endothelialization is weak (score 5). With selective peptide grafting or endothelial-friendly topography it could approach Formula 10, but as-is it trails on combined thromboresistance and SMC suppression.
- Near-Optimal but Second Place:
  - Formula 5 (GelMA + PEG): Very competitive profile with better endothelialization than Formula 10, but slightly less potent SMC inhibition and hemocompatibility as an inherent, unmodified chemistry. If rapid endothelialization is a strategic priority, Formula 5 is the most balanced alternative.

Note on reference anchoring and data gaps:
- Young’s modulus reference used: 0.2–1.0 MPa (hydrated, physiologic range). All scores assume tunable synthesis within this range.
- Where direct, blood-facing SMC or cytokine data were limited (e.g., starch/chitin/cellulose composites), conservative midline scores (≈5–6) were applied and flagged implicitly by not awarding higher values.

# Run 4 response, Temperature =0.0:

**1. QUANTIFIED SCORING (.CSV FORMAT)**
```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1 (Gel + GelMA),7.5,7.0,8.0,5.5,7.0,6.0,41.0
Formula 2 (PAM + Gel),8.5,8.0,7.0,6.0,6.5,6.0,42.0
Formula 3 (Chitosan + GelMA),7.5,7.0,7.0,7.0,5.5,3.5,37.5
Formula 4 (GelMA + Silk Fibroin),9.0,7.0,8.0,6.0,8.0,7.0,45.0
Formula 5 (GelMA + PEG),9.0,9.0,8.0,7.5,8.5,9.0,51.0
Formula 6 (Starch + GelMA),7.0,6.0,7.0,6.0,5.5,3.5,35.0
Formula 7 (Chitin + GelMA),8.0,6.5,6.5,5.0,4.5,3.5,34.0
Formula 8 (GelMA + Cellulose),9.0,8.0,8.0,6.0,7.5,8.0,46.5
Formula 9 (PAM + PVA),9.0,8.0,5.0,8.0,8.0,8.5,46.5
Formula 10 (PAM + PEG),9.0,9.0,4.5,8.5,8.5,9.0,48.5
```

**2. THE WINNER (Calculated Result)**
- Selected Formula: Formula 5 (GelMA + PEG)
- One-Sentence Rationale: It best balances artery-matched mechanics with high-yet-controlled swelling and superior hemocompatibility, while promoting endothelial coverage and limiting SMC overgrowth.

**3. THE "WHY" (Detailed Logic for the Winner)**
- Mechanical Fit: Reference range used for human coronary artery circumferential Young’s modulus at physiologic strain: 0.2–1.0 MPa. GelMA-PEG IPNs/semi-IPNs are tunable via GelMA methacrylation degree, polymer wt%, and PEG (e.g., PEGDA/PEGMA) crosslink density to land squarely within 0.2–1.0 MPa without brittleness, maintaining elastic resilience needed for a conformal liner.
- Swelling Profile: PEG networks offer high, predictable water uptake; blending with GelMA enables a “Goldilocks” swelling that boosts conformability and potential drug loading while avoiding lumen occlusion. Design levers to maintain safety include: limiting equilibrium swelling (e.g., Qeq ~5–10) by raising crosslink density, pre-equilibrating the liner ex vivo, and using anisotropic or gradient crosslinking so radial swelling is constrained while circumferential compliance remains.

**4. THE SAFETY AUDIT (Winner's Pros & Cons)**
- Biological "Green Flags":
  - Endothelialization: GelMA provides cell-adhesive motifs (e.g., RGD-like sites) supporting endothelial attachment and rapid re-endothelialization; PEG modulates nonspecific adsorption, helping bias toward controlled, monolayer-forming EC coverage rather than exuberant multilayers.
  - SMC-inhibition: PEG’s antifouling character reduces SMC adhesion and phenotypic switching to synthetic states; with tuned GelMA fraction, EC>SMC selectivity is enhanced.
  - Anti-inflammation: PEG reduces protein adsorption and complement activation; GelMA is generally well tolerated when photoinitiator/leachables are minimized. Degradation to peptides and PEG fragments is typically neutral in pH and non-irritating.
  - Thrombogenicity: PEG lowers platelet adhesion/activation; GelMA’s proteinaceous nature is masked/modulated by PEG, yielding strong hemocompatibility for blood-contacting liners.
- Potential "Red Flags" & Phantom Factors:
  - Thrombosis/Inflammation from processing residues: Methacrylate and photoinitiator leachables, and unreacted acrylates can elevate platelet activation and cytotoxicity; strict purification and high conversion photopolymerization are essential.
  - PEG oxidation over time: Oxidative environments can degrade PEG, reducing antifouling performance; stabilize with antioxidant strategies or by introducing urethane linkages and using medical-grade PEG.
  - Enzymatic remodeling mismatch: GelMA may remodel faster than desired under high MMP activity; risk of thinning. Mitigate via crosslink density, protease-cleavable crosslinkers with tuned kinetics, or a thin reinforcing mesh.
  - Swelling-induced lumen narrowing: Prevent by pre-equilibrating, limiting radial free-swelling via circumferential fiber reinforcement or graded crosslinking, and validating worst-case in pulsatile flow testing.

**5. REJECTED CANDIDATES (Brief Autopsy)**
- Rejected due to Thrombosis Risk (Thrombogenicity <4):
  - Formula 3 (Chitosan + GelMA): Chitosan’s cationic, hemostatic nature promotes platelet activation and clotting despite GelMA.
  - Formula 6 (Starch + GelMA): Starch-based components are hemostatic and strongly water-swelling, risking clot formation and lumen compromise.
  - Formula 7 (Chitin + GelMA): Chitin can be pro-hemostatic and immunostimulatory, increasing thrombotic and inflammatory risk.
- Penalized for Endothelialization Deficits (low-to-marginal EC adhesion inherent to chemistry):
  - Formula 9 (PAM + PVA) and Formula 10 (PAM + PEG): Strongly antifouling, excellent hemocompatibility but weak intrinsic EC adhesion; would require explicit biofunctionalization beyond listed chemistries.
- Strong but Outscored (balanced yet not top of the Pareto front):
  - Formula 4 (GelMA + Silk Fibroin): Good mechanics/biocompatibility, but lower swelling flexibility and moderate thrombogenicity versus PEG blends.
  - Formula 8 (GelMA + Cellulose): Very good mechanical reinforcement and hemocompatibility; slightly less selective SMC control than PEG-containing systems.
- Adequate but Less Optimal Trade-offs:
  - Formula 1 (Gel + GelMA) and Formula 2 (PAM + Gel): Reasonable mechanics and EC support, but proteinaceous content modestly elevates thrombogenicity and provides less SMC suppression than PEG-containing or highly antifouling systems.

# Run 5 response, Temperature =0.0:

```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1,8,7,9,4,6,5.5,39.5
Formula 2,7.5,7.5,7.5,6.5,6.5,6.5,42
Formula 3,7,6,7,5,4.5,3.5,33
Formula 4,8.5,6,8,5.5,7,6,41
Formula 5,9,8.5,8,7.5,8.5,8.5,50
Formula 6,6.5,6.5,7,5.5,6.5,6,38
Formula 7,6.5,5.5,7,5,4,4.5,32
Formula 8,8.5,6.5,8,6,7,7,43
Formula 9,9,8,5.5,8.5,8,8.5,47.5
Formula 10,8.5,8.5,5,9,8.5,9,48.5
```

2. THE WINNER (Calculated Result)
- Selected Formula: Gelatin_methacrylate (GelMA) & Polyethylene_glycol (PEG)
- One-Sentence Rationale: It delivers the best overall balance of artery-matched mechanics, high-but-controllable swelling, pro-endothelial yet SMC-limiting surface chemistry, low inflammation, and low thrombogenicity.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: Reference range used for human coronary artery Young’s modulus at physiologic strain: 0.2–1.0 MPa (literature reports typically 0.2–0.8+ MPa depending on layer and strain). GelMA-PEG networks can be precisely tuned across this window by adjusting GelMA degree of methacrylation, PEG molecular weight and functionality (e.g., PEGDA), and crosslink density. This yields a compliant liner that avoids stress-shielding and mismatch-induced intimal hyperplasia.
- Swelling Profile: PEG provides high water uptake for conformability and drug loading; GelMA moderates network stability. By selecting a moderate crosslink density and thin-wall geometry, the construct achieves a large equilibrium swelling ratio while keeping radial expansion below lumen-occluding thresholds. Strategies like pre-hydration to final dimensions, anisotropic fiber reinforcement, or gradient crosslinking further contain radial swelling and preserve luminal patency.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Endothelialization: GelMA presents native adhesion motifs (e.g., RGD) supporting rapid endothelial coverage without excessive proliferation when diluted by PEG’s non-fouling character.
  - SMC-inhibition: PEG’s resistance to protein adsorption and cell adhesion reduces SMC attachment and the synthetic phenotype switch that drives restenosis.
  - Anti-inflammation: PEG is broadly bioinert; GelMA is generally well tolerated. Together they limit macrophage activation relative to cationic polysaccharides.
  - Thrombogenicity: PEG-rich surfaces decrease protein adsorption and platelet adhesion, lowering acute thrombosis risk while maintaining enough biological interface (via GelMA) for endothelial repair.
- Potential "Red Flags" & Phantom Factors:
  - Anti-PEG antibodies/complement activation: A growing fraction of patients have anti-PEG IgG/IgM. Mitigations include minimizing free PEG chains, using high-crosslink-density PEG networks, or considering zwitterionic alternatives (e.g., carboxybetaine) in future iterations.
  - Photoinitiator/leachables: Residual photoinitiator (e.g., Irgacure) and unreacted methacrylates can be cytotoxic/thrombogenic. Requires low-initiator formulations, complete cure, and rigorous solvent exchange.
  - Proteinaceous thrombogenicity: GelMA can modestly increase platelet interactions if overrepresented. Maintain PEG-rich surface presentation and consider heparin surface tethering if clinically indicated.
  - Degradation mismatch: GelMA is enzymatically degradable; PEG is slowly oxidatively degradable (or effectively nondegradable depending on chemistry). Balance degradation to avoid long-term persistence or premature loss of support.
  - Mechanical creep/fatigue: Validate under pulsatile coronary conditions; consider nanofiber or nanocellulose reinforcement if long-term creep is detected.

5. REJECTED CANDIDATES (Brief Autopsy)
- Elevated thrombosis risk (cationic/hemostatic backbones):
  - Formula 3 (Chitosan & GelMA): Cationic chitosan is procoagulant and can activate complement; thrombogenicity and inflammation scores too low.
  - Formula 7 (Chitin & GelMA): Similar innate immune activation and thrombosis concerns; limited swelling control.
- Over-adhesive to SMCs / risk of neointimal response without antifouling balance:
  - Formula 1 (Gelatin & GelMA), Formula 4 (GelMA & Silk), Formula 6 (Starch & GelMA): Good endothelialization but higher SMC adhesion risk and/or weaker control of swelling or long-term mechanics.
- Suboptimal endothelialization (surface too inert without bioactive cues):
  - Formula 9 (PAM & PVA), Formula 10 (PAM & PEG): Excellent anti-thrombosis and SMC inhibition, but insufficient intrinsic endothelial adhesion, risking delayed endothelialization.
- Competitive but edged out:
  - Formula 8 (GelMA & Cellulose): Strong mechanics and hemocompatibility; swelling and SMC control are good but less optimal than PEG-blended systems; overall score below the winner.
- Mechanical/swell balance acceptable but not best-in-class:
  - Formula 2 (PAM & Gelatin): Improved balance over pure gelatin systems but trails GelMA-PEG in thrombogenicity and inflammation control.

# Run 6 response, Temperature =0.0:

```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1,8,7,9,5,7,6,42
Formula 2,8,6,7,6,6,7,40
Formula 3,8,6,7,6,5,4,36
Formula 4,8,6,8,6,8,8,44
Formula 5,8,8,8,8,9,9,50
Formula 6,7,6,6,5,5,6,35
Formula 7,7,6,5,5,4,5,32
Formula 8,8,7,8,7,9,8,47
Formula 9,8,6,4,7,9,8,42
Formula 10,8,6,4,8,9,9,44
```

2. THE WINNER (Calculated Result)
- Selected Formula: Formula 5 (Gelatin_methacrylate (GelMA) & Polyethylene_glycol (PEG))
- One-Sentence Rationale: It best balances artery-matched mechanics with high-but-controlled swelling while maximizing hemocompatibility, anti-inflammation, selective endothelialization, and SMC suppression.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: Reference coronary artery Young’s modulus used across all scoring = 0.2–1.0 MPa (circumferential, small-strain literature range); GelMA–PEG interpenetrating/co-crosslinked networks reliably tune into this window via degree of methacrylation, PEG content, and crosslink density without brittleness.
- Swelling Profile: PEG provides high equilibrium water content and diffusion capacity (for conformability/drug loading), while GelMA provides a cohesive matrix; by limiting radial swelling via crosslink density and liner wall thickness, high swelling is maintained for deployment and mass transport without risking lumen encroachment, and swollen-state modulus remains in the Goldilocks zone.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Endothelialization: GelMA’s native RGD motifs promote endothelial adhesion and monolayer formation; PEG dilutes nonspecific protein adsorption to prevent hyperproliferative neotissue, supporting a thin, quiescent endothelium.
  - SMC-inhibition: PEG’s antifouling character reduces SMC adhesion and phenotypic switching; net effect favors re-endothelialization without stimulating medial hyperplasia.
  - Anti-inflammation: PEG is broadly inert; GelMA degrades enzymatically into neutral peptides; with clean photopolymerization (low initiator load, post-cure rinsing), cytokine elevations are minimal.
  - Thrombogenicity: PEG’s low protein/platelet adsorption reduces thrombus initiation; GelMA content can be kept below thresholds that expose collagen-like sequences excessively.
- Potential "Red Flags" & Phantom Factors:
  - Anti-PEG antibodies/hypersensitivity: Rare but real; screen for prior PEG hypersensitivity and consider surface presentation minimization or PEG alternatives if needed.
  - Photoinitiator/UV residues: Inadequate post-cure cleaning can provoke ROS-driven irritation; mandate low-tox initiators (e.g., LAP), controlled exposure, and exhaustive rinsing.
  - Long-term PEG oxidation/chain scission: May gradually reduce mechanical integrity; mitigate via antioxidant stabilization or periodic architecture (e.g., reinforcing microfibers) to preserve modulus in vivo.
  - Over-swelling risk: If crosslinking is too low, radial expansion could reduce lumen; prehydrate to equilibrium before implantation and cap wall thickness to maintain inner diameter margin.

5. REJECTED CANDIDATES (Brief Autopsy)
- Primary thrombosis risk (cationic/hemostatic backbones, platelet activation):
  - Formula 3 (Chitosan & GelMA): Cationic surfaces increase platelet activation; inflammation risk elevates thrombotic cascade.
  - Formula 7 (Chitin & GelMA): Innate immune activation and poor hemocompatibility compared with winners.
- Poor endothelialization without bioactive cues (unless further functionalized):
  - Formula 9 (PAM & PVA), Formula 10 (PAM & PEG): Strong antifouling suppresses both EC and SMC; endothelial coverage likely too slow/insufficient without added ligands.
- Swelling/instability concerns (risk of lumen encroachment or hydrolytic softening):
  - Formula 2 (PAM & Gelatin), Formula 9 (PAM & PVA), Formula 10 (PAM & PEG): Very high swelling propensity demands aggressive constraints; feasible but less forgiving.
  - Formula 6 (Starch & GelMA): Hydrolytic byproducts and mechanical drift under blood exposure; higher uncertainty.
- Balanced but outperformed biologically:
  - Formula 1 (Gelatin & GelMA): Good endothelialization but higher thrombogenicity and SMC permissiveness than the winner.
  - Formula 4 (GelMA & Silk Fibroin): Excellent hemocompatibility and stability but lower swelling performance vs. requirement and neutral SMC control.
  - Formula 8 (GelMA & Cellulose): Very strong overall runner-up; slightly lower swelling capacity and SMC selectivity versus GelMA–PEG.

# Run 7 response, Temperature =0.0:

```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1 (Gel + GelMA),8,7,9,5,6,5,40
Formula 2 (PAM + Gel),9,7,7,5,6,6,40
Formula 3 (Chitosan + GelMA),8,6,7,5,4,3,33
Formula 4 (GelMA + Silk Fibroin),9,7,8,6,8,7,45
Formula 5 (GelMA + PEG),9,9,8,8,9,9,52
Formula 6 (Starch + GelMA),7,6,7,5,6,6,37
Formula 7 (Chitin + GelMA),8,7,7,5,5,5,37
Formula 8 (GelMA + Cellulose),9,8,8,7,8,8,48
Formula 9 (PAM + PVA),9,8,5,8,8,8,46
Formula 10 (PAM + PEG),9,9,5,9,9,9,50
```

2. THE WINNER (Calculated Result)
- Selected Formula: Formula 5 (GelMA + PEG)
- One-Sentence Rationale: It offers the best combined match to coronary artery mechanics with a high yet controllable swelling ratio and the most favorable hemocompatibility/anti-inflammatory/SMC-inhibition balance.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: Using a reference human coronary artery Young’s modulus of ~0.2–1.0 MPa at physiologic strain, GelMA–PEG IPN/co-networks can be tuned (via GelMA methacrylation degree, PEG MW and crosslink density) to land squarely in this range while retaining fatigue resistance under pulsatile loading.
- Swelling Profile: PEG drives high water uptake for conformability and potential drug loading, while crosslink density and PEG:GelMA ratio allow tight control of equilibrium swelling; radial expansion can be capped (e.g., via higher circumferential crosslinking or a thin-wall design) to avoid lumen occlusion yet still achieve atraumatic apposition to the intima.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Endothelialization: GelMA provides controlled adhesive ligands (e.g., native RGD motifs) to support re-endothelialization without excessive proliferation if ligand density is moderated.
  - SMC-inhibition: PEG’s protein-repellent character limits SMC adhesion and phenotype switching toward the synthetic, reducing neointimal hyperplasia risk.
  - Anti-inflammation: PEG’s low protein adsorption blunts complement/cytokine activation; GelMA degradation products are generally well tolerated.
  - Thrombogenicity: PEG reduces platelet adhesion/activation; blending with GelMA balances cell integration while maintaining low thrombogenicity relative to collagen-rich surfaces.
- Potential "Red Flags" & Phantom Factors:
  - Anti-PEG antibodies/CARPA: Increasing population prevalence of anti-PEG antibodies could trigger complement activation in rare cases; consider PEG molecular architecture and thorough hemocompatibility testing.
  - Photoinitiator/methacrylate residuals: Unreacted methacrylates or photoinitiator (e.g., Irgacure) can be cytotoxic/pro-inflammatory; use visible-light systems (eosin Y/Riboflavin), optimize conversion, and post-cure washing.
  - Platelet interaction via GelMA: Excess ligand density may elevate platelet binding; mitigate by PEG-rich surface presentation and/or heparin/NO-functional handles if needed.
  - Long-term oxidative degradation of PEG: Track mechanical drift and leachables under oxidative stress; select stabilized PEG and validate durability under accelerated aging.

5. REJECTED CANDIDATES (Brief Autopsy)
- Elevated thrombosis risk (fatal or near-fatal flaw without heavy mitigation):
  - Formula 3 (Chitosan + GelMA): Cationic chitosan promotes platelet activation and can be pro-inflammatory; thrombogenicity score 3.
- Insufficient SMC control (would require additional drug/functionalization):
  - Formula 1 (Gel + GelMA), Formula 2 (PAM + Gel), Formula 6 (Starch + GelMA), Formula 7 (Chitin + GelMA): Bioactive/cell-adhesive backbones without antifouling components scored ~5 on SMC inhibition.
- Endothelialization deficit (non-fouling but needs ligand grafting for re-lining):
  - Formula 9 (PAM + PVA), Formula 10 (PAM + PEG): Excellent thromboresistance/anti-inflammation and SMC control, but weak intrinsic endothelialization (score 5) unless RGD/ECM peptides or avidin–biotin endothelial capture strategies are added.
- Good but outperformed on composite balance:
  - Formula 4 (GelMA + Silk Fibroin): Strong mechanics and hemocompatibility, but less antithrombotic than PEG blends and slightly less controllable swelling.
  - Formula 8 (GelMA + Cellulose): Very balanced and strong runner-up, with good mechanics, low thrombogenicity, and stable swelling; narrowly trails the winner on SMC-inhibition and hemocompatibility.

# Run 8 response, Temperature =0.0:

Step 1: Data normalization and reference anchoring
- Target Young’s Modulus (human coronary artery): I will use 0.2–1.0 MPa (200–1000 kPa) as the compliance-matching range based on commonly cited arterial media values in the literature.
- All mechanical judgments below are made against this 0.2–1.0 MPa target and assume optimization of crosslinking density and polymer content to stay within this range.

1. QUANTIFIED SCORING (.CSV FORMAT)
```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1 (Gel + GelMA),8,8,8,6,7,6,43
Formula 2 (PAM + Gel),8,8,7,6,6,6,41
Formula 3 (Chitosan + GelMA),8,7,6,5,4,3,33
Formula 4 (GelMA + Silk Fibroin),9,7,8,6,8,8,46
Formula 5 (GelMA + PEG),9,9,8,8,9,9,52
Formula 6 (Starch + GelMA),7,6,7,6,6,6,38
Formula 7 (Chitin + GelMA),8,6,6,5,4,4,33
Formula 8 (GelMA + Cellulose),9,7,8,7,8,8,47
Formula 9 (PAM + PVA),9,8,5,8,7,8,45
Formula 10 (PAM + PEG),9,9,4,9,8,9,48
```

2. THE WINNER (Calculated Result)
- Selected Formula: Formula 5 (GelMA + PEG)
- One-Sentence Rationale: It best matches arterial modulus while delivering high, controllable swelling, low thrombogenicity, balanced endothelialization, SMC inhibition, and a favorable anti-inflammatory profile.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: GelMA-PEG networks can be tuned (via GelMA degree of methacrylation, PEG molecular weight and crosslinker content) to 0.2–1.0 MPa, matching coronary compliance and minimizing compliance mismatch–driven intimal hyperplasia.
- Swelling Profile: PEG contributes high, fast water uptake for deployment and drug carriage; crosslink density and PEG content allow setting an upper bound on equilibrium swelling so the liner conforms without lumen occlusion. Design control options include slightly higher crosslink density at the blood-contact surface and/or incorporating low-swelling PEGDA segments to cap radial expansion while preserving axial conformability.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Endothelialization: GelMA provides cell-adhesive motifs (e.g., RGD) supporting endothelial coverage without excessive neointimal overgrowth when balanced with PEG’s antifouling character.
  - SMC-inhibition: PEG’s inherent anti-adhesive/antifouling character reduces SMC attachment and phenotypic switching; the blend allows selective endothelial preference over SMCs.
  - Anti-inflammation: PEG is broadly inert; GelMA degrades to neutral peptides; low risk of acidic byproducts or strong cytokine activation when photoinitiator residues are minimized.
  - Thrombogenicity: PEG notably reduces protein adsorption and platelet adhesion; early hemocompatibility is favorable while endothelialization progresses.
- Potential "Red Flags" & Phantom Factors:
  - Photoinitiator/leachables: Residual methacrylate or initiator (e.g., LAP/Irgacure) must be minimized; rigorous post-cure rinsing and degree-of-conversion verification required.
  - Anti-PEG antibodies/CARPA: Rare but documented hypersensitivity to PEG in some patients; risk is lower for crosslinked surfaces but warrants hemocompatibility testing.
  - Gelatin source: Use recombinant human gelatin or highly purified species-matched gelatin to reduce immunogenicity; verify low endotoxin.
  - Swelling-lumen balance: Set and validate a maximum radial swelling ratio and deploy with geometric safeguards (e.g., anisotropic crosslinking or physical constraints) to prevent occlusion.
  - Long-term stability: Monitor oxidative degradation of PEG under blood-contact conditions and ensure fatigue resistance under pulsatile strain.

5. REJECTED CANDIDATES (Brief Autopsy)
- Rejected primarily due to thrombosis risk:
  - Formula 3 (Chitosan + GelMA): Strong hemostatic, cationic surface drives platelet adhesion (thrombogenicity score 3) and pro-inflammatory signaling; unacceptable for blood-contact without substantial mitigation.
  - Formula 7 (Chitin + GelMA): Borderline thrombogenicity (4) and pro-inflammatory risk from polysaccharide backbone.
- Endothelialization too low without heavy biofunctionalization:
  - Formula 10 (PAM + PEG): Very low endothelial adhesion (4) despite excellent mechanics, swelling, and hemocompatibility; would require added ligands to be viable.
  - Formula 9 (PAM + PVA): Poor endothelialization (5) limits spontaneous healing; needs surface modification.
- Swelling stability or structural concerns:
  - Formula 6 (Starch + GelMA): High swelling but risk of mechanical softening and less predictable degradation in blood; marginal overall performance.
- Generally solid but outperformed:
  - Formula 4 (GelMA + Silk Fibroin) and Formula 8 (GelMA + Cellulose): Strong, hemocompatible, and bioactive, but offer less tunable antifouling to selectively deter SMCs compared with GelMA-PEG.
  - Formula 1 and Formula 2: Biologically acceptable yet with higher thrombogenicity (gelatin content) and/or residual monomer concerns (PAM), and less selective SMC control than the winner.

# Run 9 response, Temperature =0.0:

```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1,8,7,8,4,7,5,39
Formula 2,8,6,6,5,6,6,37
Formula 3,8,6,7,5,4,4,34
Formula 4,9,6,8,4,6,6,39
Formula 5,9,8,7,7,8,8,47
Formula 6,7,5,7,5,6,6,36
Formula 7,8,6,7,5,5,5,36
Formula 8,9,7,7,6,8,8,45
Formula 9,9,8,5,8,7,8,45
Formula 10,9,7,4,9,8,9,46
```

2. THE WINNER (Calculated Result)
- Selected Formula: Formula 5 (Gelatin_methacrylate (GelMA) & Polyethylene_glycol (PEG))
- One-Sentence Rationale: It best balances artery-matched mechanics with high-but-controlled swelling while achieving pro-endothelial, low-thrombogenic, low-inflammatory, and SMC-suppressive surface chemistry.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: Reference arterial Young’s modulus used: 0.2–1.0 MPa (human coronary artery, physiologic pressure, small-strain regime). GelMA-PEG IPN/co-network systems can be tuned (polymer wt%, PEG functionality, degree of methacrylation, crosslink density) to sit squarely in this 0.2–1.0 MPa band without becoming brittle, hence the 9/10 Mechanical_Safety score.
- Swelling Profile: PEG provides high water uptake; GelMA tempers and stabilizes that swelling. By using moderate GelMA content, higher PEG MW with higher functionality but controlled crosslink density, and potentially anistropic/constraint-guided curing, the network reaches high swelling for apposition/drug loading while maintaining dimensional stability to avoid lumen choke—hence 8/10.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Endothelialization: GelMA presents natural cell-adhesive motifs; a modest fraction of PEG dampens non-specific protein adsorption, giving a “just-right” endothelial adhesion window (score 7) without overstimulating tissue overgrowth.
  - SMC-inhibition: PEG’s non-fouling character reduces SMC attachment/migration; with limited GelMA exposure or surface patterning, SMC proliferation can be kept low (score 7).
  - Anti-inflammation: PEG is highly inert; GelMA degrades to benign peptides. With complete photopolymerization and post-cure washes to remove initiator residues, inflammatory signaling stays low (score 8).
  - Thrombogenicity: PEG reduces protein adsorption and platelet adhesion; with rapid endothelial coverage from GelMA cues, thrombosis risk is minimized (score 8).
- Potential "Red Flags" & Phantom Factors:
  - Residual photoinitiator/methacrylate groups can trigger cytotoxicity/inflammation—mitigate with low-tox initiators (e.g., LAP), full conversion, and aggressive rinsing.
  - If the GelMA fraction is too high at the blood interface, platelet adhesion may increase—mitigate by PEG-rich surface presentation, heparin/NO functionalization, or endothelial-first surface patterning.
  - Hydrogel anisotropy vs arterial mechanics: arteries are fiber-reinforced and anisotropic; an isotropic gel liner can mismatch compliance under pulsatile load—mitigate via fiber reinforcement or gradient crosslinking.
  - Degradation products: PEG fragments (neutral) and gelatin peptides (near neutral) are not expected to acidify local pH meaningfully; monitor for rare PEG hypersensitivity (low incidence).

5. REJECTED CANDIDATES (Brief Autopsy)
- Elevated thrombogenicity risk (cationic polysaccharide-driven, complement/platelet activation):
  - Formula 3 (Chitosan & GelMA): Prothrombotic and pro-inflammatory tendencies of chitosan (scores 4/4 for thrombogenicity/anti-inflammation) despite decent mechanics and endothelialization.
- Over-adhesive, SMC-permissive matrices (risk of intimal hyperplasia without further anti-SMC strategy):
  - Formula 1 (Gel + GelMA), Formula 4 (GelMA + Silk Fibroin): Strong endothelialization but low SMC-inhibition (4/10), risking restenosis unless supplemented with anti-SMC cues.
- Swelling control risk or mechanical fragility under high-swelling targets:
  - Formula 2 (PAM + Gel): High PAM swelling with potential instability unless tightly constrained.
  - Formula 6 (Starch + GelMA): Tends toward over-swelling and mechanical softening as starch hydrates/degrades.
- Low intrinsic endothelialization (would require explicit biofunctionalization to be viable):
  - Formula 9 (PAM + PVA), Formula 10 (PAM + PEG): Strong SMC inhibition and hemocompatibility but poor endothelialization (5 and 4, respectively). Note: Formula 10 scored highly overall but is deprioritized versus the winner due to delayed endothelial coverage risk in vivo without added ligands.
- Balanced but second-tier:
  - Formula 7 (Chitin + GelMA): Acceptable across categories but moderate inflammation/thrombogenicity risks and limited advantages over the winner.
  - Formula 8 (GelMA + Cellulose): Very good hemocompatibility and mechanics; slightly less adaptable for high swelling versus GelMA-PEG and somewhat lower SMC control, hence runner-up tier.

# Run 10 response, Temperature =0.0:

Step 1: Data normalization and reference anchoring
- Human coronary artery Young’s modulus reference: I will use 0.3–1.0 MPa (physiologic-range tangent modulus commonly reported for coronary arteries). All mechanical assessments are anchored to this range and expressed in MPa terms.

1. QUANTIFIED SCORING (.CSV FORMAT)
```csv
Candidate,Mechanical_Safety,Swelling_Performance,Endothelialization,SMC_inhibition,Anti_inflammation,Thrombogenicity,Total_Score
Formula 1 (Gel + GelMA),7,6,8,5,6,5,37
Formula 2 (PAM + Gel),8,5,7,6,5,5,36
Formula 3 (Chitosan + GelMA),7,6,6,4,4,3,30
Formula 4 (GelMA + Silk Fibroin),8,6,8,5,6,5,38
Formula 5 (GelMA + PEG),8,8,8,7,8,9,48
Formula 6 (Starch + GelMA),6,6,7,5,6,5,35
Formula 7 (Chitin + GelMA),7,6,5,3,3,3,27
Formula 8 (GelMA + Cellulose),9,7,7,7,8,8,46
Formula 9 (PAM + PVA),9,6,4,8,5,7,39
Formula 10 (PAM + PEG),8,6,4,8,6,8,40
```

2. THE WINNER (Calculated Result)
- Selected Formula: Formula 5 (GelMA + PEG)
- One-Sentence Rationale: It best balances artery-matched mechanics and high-but-controllable swelling with an intrinsically hemocompatible, low-fouling, pro-endothelium chemistry that also suppresses SMC adhesion and inflammation risk.

3. THE "WHY" (Detailed Logic for the Winner)
- Mechanical Fit: With appropriate macromer MW and crosslink density (e.g., GelMA degree of methacrylation tuned and PEGDA/PEGMA fraction optimized), GelMA+PEG composites can reproducibly land in the 0.3–0.8 MPa range in the swollen state, directly within the 0.3–1.0 MPa coronary target. PEG provides network stability; GelMA adds toughness without overshooting stiffness like silk-reinforced systems might.
- Swelling Profile: PEG-rich networks give high equilibrium swelling for conformal apposition and drug loading, yet the crosslink density can cap volumetric swelling to avoid lumen loss. Practically, target a radial swelling ratio that yields ≤10–15% diameter change in vivo while leveraging axial/bulk swelling for deployment. PEG’s predictable osmotic swelling and GelMA’s tunability minimize uncontrolled expansion and preserve post-deployment mechanical integrity.

4. THE SAFETY AUDIT (Winner's Pros & Cons)
- Biological "Green Flags":
  - Endothelialization: GelMA provides integrin-binding motifs (e.g., RGD-like sequences) favoring rapid endothelial coverage; PEG helps present a cleaner interface that biases endothelial over SMC adhesion when combined with shear cues.
  - SMC-inhibition: PEG’s low-fouling nature reduces non-specific protein adsorption and SMC attachment, helping prevent neointimal hyperplasia; the GelMA fraction can be kept modest to avoid SMC-friendly surfaces deeper in the wall.
  - Anti-inflammation: PEG is well-known for dampening protein adsorption and foreign-body response; GelMA degradation fragments are generally benign peptides.
  - Thrombogenicity: PEG is intrinsically anti-fouling and reduces platelet adhesion; with GelMA kept below the threshold that exposes excessive pro-coagulant protein domains, the net surface is low-thrombogenic.
- Potential "Red Flags" & Phantom Factors:
  - Photopolymerization residues: Unreacted methacrylates and photoinitiators (e.g., LAP/Irgacure) can be cytotoxic or pro-inflammatory if not fully consumed/extracted; requires high conversion, post-cure leaching, and analytical verification.
  - Anti-PEG immune response: Rare anti-PEG antibodies have been reported clinically; monitor for hypersensitivity risks and consider surface presentation strategies that minimize free-PEG antigenicity.
  - Fatigue/creep under pulsatile load: PEG-rich networks can creep; mitigate with interpenetrating network design, modest GelMA content for toughness, and fatigue testing under coronary pulse conditions.
  - Swelling-induced lumen loss: Requires strict control of polymer fraction and crosslink density to ensure in vivo radial expansion remains below occlusive thresholds; design anisotropy can further bias swelling away from the lumen.

5. REJECTED CANDIDATES (Brief Autopsy)
- Elevated thrombosis risk (inherent chemistry):
  - Chitosan + GelMA (Formula 3): Cationic chitosan is hemostatic, promotes platelet adhesion; thrombogenicity score 3.
  - Chitin + GelMA (Formula 7): Similar cationic/insoluble polysaccharide issues; thrombogenicity score 3.
- Insufficient endothelialization (anti-adhesive surfaces) without compensating biology:
  - PAM + PVA (Formula 9): Both low-fouling; endothelialization score 4; although good SMC suppression, net re-endothelialization is weak.
  - PAM + PEG (Formula 10): Very anti-adhesive; endothelialization score 4; risk of delayed endothelial coverage.
- Inflammation/biocompatibility concerns (safety-first penalty):
  - PAM-containing systems (Formulas 2, 9, 10): Residual acrylamide monomer risk and uncertain long-term implant safety led to anti-inflammation penalties (5–6).
- Modulus/swell coupling not ideal or biology less balanced:
  - Gel + GelMA (Formula 1): Good endothelialization but moderate thrombogenicity and SMC control; mechanical stability under high swelling is borderline.
  - GelMA + Silk Fibroin (Formula 4): Mechanics are strong but thrombogenicity and SMC control are only middling; swelling/conformability limited.
  - Starch + GelMA (Formula 6): Swelling is high but mechanical ceiling is modest; degradation to sugars raises osmotic/biofilm concerns without clear thrombosis advantage.
  - GelMA + Cellulose (Formula 8): Strong runner-up with excellent mechanics, hemocompatibility, and balanced biology; slightly less tunable anti-fouling than PEG for SMC suppression and thrombosis, hence narrowly second place.

Notes on Step 1 anchoring
- All mechanical judgments reflect achievable swollen-state moduli tuned to 0.3–1.0 MPa.
- Swelling assessments assume deployment-relevant hydration and physiologic ionic strength.

If you want, I can propose target formulation windows (PEG MW, GelMA degree of methacrylation, and crosslinker/initiator ranges) to hit a specific modulus (e.g., 0.6 MPa) with ≤10% radial expansion post-implant.

